Impact of Imatinib on reducing the painful crisis in patients with sickle cell disease

Authors: Mojtaba Karimi, Mohammad Bahadoram, Ladan Mafakher, Mohammadhossein Rastegar

Source: Hematology, Transfusion and Cell Therapy, Vol 46, Iss 4, Pp 387-392 (2024)

Subject Terms: Sickle cell anemia, Painful crisis, Hydroxyurea (HU), Imatinib, Analgesics, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2531137923001475; https://doaj.org/toc/2531-1379

Access URL: https://doaj.org/article/ef62ead8bea743d3bfcaa8b2859af7c6

Auxin-Glucose Conjugation Protects the Rice (Oryza sativa L.) Seedlings Against Hydroxyurea-Induced Phytotoxicity by Activating UDP-Glucosyltransferase Enzyme

Authors: Vimalraj Kantharaj, Nirmal Kumar Ramasamy, Young-Eun Yoon, Mi Sun Cheong, Young-Nam Kim, Keum-Ah Lee, Vikranth Kumar, Hyeonji Choe, Song Yeob Kim, Hadjer Chohra, Yong Bok Lee

Source: Frontiers in Plant Science, Vol 12 (2022)

Subject Terms: auxin, auxin conjugate, hydroxyurea (HU), reactive oxygen species (ROS), ribonucleotide reductase (RNR), uridine 5′-diphosphate-glucosyltransferase (UGT), Plant culture, SB1-1110

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fpls.2021.767044/full; https://doaj.org/toc/1664-462X

Access URL: https://doaj.org/article/3cb2633f671d48b2b87202ef138bd66e

Do Genetic Polymorphisms Affect Fetal Hemoglobin (HbF) Levels in Patients With Sickle Cell Anemia Treated With Hydroxyurea? A Systematic Review and Pathway Analysis

Authors: Rahyssa Rodrigues Sales, Bárbara Lisboa Nogueira, Jéssica Abdo Gonçalves Tosatti, Karina Braga Gomes, Marcelo Rizzatti Luizon

Source: Frontiers in Pharmacology, Vol 12 (2022)

Subject Terms: BCL11A gene, fetal hemoglobin (HbF), genetic polymorphisms, hydroxyurea (HU) therapy, pathway analysis, pharmacogenetics, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2021.779497/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/e0a5758e6370443da27d300af6210e33

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

Authors: Konstantinos Liapis, Ioannis Kotsianidis

Source: Frontiers in Oncology, Vol 11 (2021)

Subject Terms: first-line treatment, hypomethylating agents, azacitidine (5-AzaC), decitabine (DAC), cytotoxic (or anti-neoplastic) chemotherapeutic agents, hydroxyurea (hu), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.801524/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/a66d4ae2e0b041fd9d7ea02d372b1ddb

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.